Equipment Trends in Advanced Solid-Dosage Drug Manufacturing: INTERPHEX Keynote Part 3
Fernando Muzzio, PhD, Distinguished Professor of Chemical and Biochemical Engineering at Rutgers University, spoke about trends in continuous manufacturing of OSD drugs.
Equipment and advanced manufacturing approaches to meet the evolving needs for solid-dosage drugs include continuous manufacturing, containment strategies, Industry 4.0 tools, and techniques for optimizing oral solid dosage (OSD) form manufacturing. “Equipment Trends in Advanced Solid-Dosage Drug Manufacturing” was part of a keynote series at INTERPHEX 2021 on Oct. 19, 2021.
The session was moderated by Jennifer Markarian, manufacturing editor, Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International. In this video, Jennifer interviewed Fernando Muzzio, PhD, Distinguished Professor of Chemical and Biochemical Engineering at Rutgers University about trends in continuous manufacturing of OSD drugs.
This video is part 3 of 5. The other speakers in this session were:
- Part 1: Dave DiProspero, Director Pharmaceutical Process Technology, CRB
- Part 2: Johannes Khinast, PhD, Institute for Process and Particle Engineering in the Research Center Pharmaceutical Engineering (RCPE) at the Graz University of Technology in Austria.
- Part 4: Sharon Nowak, Business Development Manager, Coperion K-Tron USA Food & Pharmaceutical Industries
- Part 5: Gernot Warnke, Head of R&D, JRS Pharma.
Watch other videos in this keynote series:
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
